axitinib + capecitabine + cisplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms, Advanced Gastric Cancer
Trial Timeline
Apr 1, 2009 → Oct 1, 2012
NCT ID
NCT00842244About axitinib + capecitabine + cisplatin
axitinib + capecitabine + cisplatin is a phase 1 stage product being developed by Pfizer for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00842244. Target conditions include Stomach Neoplasms, Advanced Gastric Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00842244 | Phase 1 | Completed |
Competing Products
20 competing products in Stomach Neoplasms